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ABSTRACT
Patients with primary HER2-positive breast cancer benefit from HER2-targeted 
therapies. Nevertheless, a significant proportion of these patients die of disease 
progression due to mechanisms of drug resistance. MicroRNAs (miRNAs) are emerging as 
critical core regulators of drug resistance that act by modulating the epithelial- 
to-mesenchymal transition (EMT) and cancer-related immune responses. In this study, 
we investigated the association between the expression of a specific subset of 14 miRNAs 
involved in EMT processes and immune functions and the response to neoadjuvant 
trastuzumab and chemotherapy in 52 patients with HER2-overexpressing breast tumors. 
The expression of only a single miRNA, miR-21, was significantly associated with residual 
disease (p = 0.030) and increased after trastuzumab-chemotherapy (p = 0.012). 
A target prediction analysis coupled with in vitro and in vivo validations revealed 
that miR-21 levels inversely correlated with the expression of PTEN (rs = −0.502; 
p = 0.005) and PDCD4 (rs = −0.426; p = 0.019), which differentially influenced the 
drug sensitivity of HER2-positive breast cancer cells. However, PTEN expression was 
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only marginally associated with residual disease. We further demonstrated that miR-
21 was able to affect the response to both trastuzumab and chemotherapy, triggering 
an IL-6/STAT3/NF-κB-mediated signaling loop and activating the PI3K pathway. Our 
findings support the ability of miR-21 signaling to sustain EMT and shape the tumor 
immune microenvironment in HER2-positive breast cancer. Collectively, these data 
provide a rationale for using miR-21 expression as a biomarker to select trastuzumab-
chemotherapy-resistant HER2-positive breast cancer patients who may benefit from 
treatments containing PI3K inhibitors or immunomodulatory drugs.
INTRODUCTION
HER2-overexpressing breast cancer represents 
approximately 20% of human breast cancers and is 
associated with an increased risk of tumor recurrence 
and reduced overall survival [1, 2]. The overexpression 
of HER2 enables the constitutive activation of growth 
factor signaling pathways and thereby serves as an 
oncogenic driver of breast cancer [3]. Despite the 
clinical benefit of HER2-targeted therapies, a substantial 
percentage of patients die of disease progression due 
to drug resistance [1–5]. Elucidating the molecular 
pathways involved in trastuzumab resistance has been 
difficult due to the variety of mechanisms of action 
of this drug. Multiple mechanisms of resistance have 
been proposed, including the deregulation of the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway, 
which is caused by activating mutations of PIK3CA 
or a loss of phosphatase and tensin homolog (PTEN), 
the reduced receptor-antibody binding affinity, and 
the increased signaling via alternative HER and 
non-HER family receptor tyrosine kinases [3–9]. 
However, final validations based on analyses of human 
tumor samples have been limited and are not entirely 
reproducible [3, 10]. Furthermore, trastuzumab in 
either the early or metastatic setting is administered 
with cytotoxic chemotherapy, which may be a further 
potential confounding factor in the search for specific 
predictive clinical biomarkers of drug resistance. 
Recently, additional pathways have been demonstrated 
to contribute to the resistance of HER2-positive breast 
tumors to trastuzumab and chemotherapy. Epithelial-to-
mesenchymal transition (EMT) is a central biological 
event that allows cancer cells to avoid apoptosis 
and cellular senescence, which contributes to tumor 
progression [11]. Anti-HER2 and chemotherapeutic 
agents have been shown to increase the number of cells 
with mesenchymal traits and contribute to multidrug 
resistance in breast cancer [12–16]. Furthermore, the 
overexpression of HER2 itself regulates EMT by directly 
activating downstream signaling, such as the PI3K 
pathway, and the induction of IL-6 release from cancer 
cells [15, 17]. Indeed, IL-6 has been demonstrated to 
activate STAT3/NF-κB signaling, which consequently 
sustains EMT in breast cancer, and to modulate the 
tumor microenvironment, linking inflammation to 
cancer progression and drug resistance [13, 17–21]. 
Therefore, a comprehensive molecular understanding of 
the pathways associated with resistance to trastuzumab 
and chemotherapy might greatly aid the development of 
more effective targeted therapies, whereas the discovery 
of clinical molecular predictors of response will allow a 
more personalized treatment approach for patients with 
HER2-amplified breast cancer.
In recent years, microRNAs (miRNAs), a class of 
small non-coding RNAs that regulate gene expression, 
have emerged as crucial regulators of the drug response 
that act by shaping the tumor immune microenvironment 
and modulating EMT [22–26]. Hence, identifying and 
targeting miRNAs that regulate pathways involved in 
tumor-associated inflammation and EMT may result in an 
effective integrative approach to overcome drug resistance 
in HER2-overexpressing breast cancers. In this study, 
we investigated the association and biological role of a 
specific subset of miRNAs involved in EMT and tumor-
associated immune pathways. Specifically, we evaluated 
the response to neoadjuvant trastuzumab and chemotherapy 
in two cohorts of HER2-positive breast cancer patients. 
Furthermore, we identified the molecular mechanisms 
underlying miRNA-mediated drug resistance using in vitro 
and in vivo assays.
RESULTS
Overexpression of miR-21 is associated with 
resistance to neoadjuvant trastuzumab-
chemotherapy in HER2-positive breast cancer 
patients
Based on a comprehensive literature review, we 
selected 14 functionally relevant miRNAs involved in the 
regulation of EMT and anti-tumor immune response and 
evaluated their clinical significance in primary HER2-
positive (n = 22) and HER2-negative (n = 21) breast 
cancer patients who received neoadjuvant trastuzumab-
chemotherapy or chemotherapy alone, respectively 
(Table 1, Supplementary Table 1). Within this subset of 
miRNAs, miR-373 and miR-18b were not detectable in 
the majority of samples and were consequently excluded 
from subsequent analyses. We found that only a single 
miRNA, miR-21, was significantly differentially 
expressed between HER2-positive patients who achieved 
a pathological complete response (pCR) and patients with 
residual disease (RD) ( p = 0.030) (Table 1). None of the 
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miRNAs analyzed correlated with drug response in HER2-
negative patients, suggesting that miR-21 may be a specific 
biomarker of resistance for HER2-positive breast cancer 
(Table 1). A further analysis of an additional cohort of 30 
HER2-positive breast cancers (Supplementary Table 1) 
confirmed that miR-21 overexpression was associated 
with RD ( p = 0.012) (Figure 1A), indicating that miR-21 
is indeed involved in resistance to neoadjuvant treatment 
consisting of trastuzumab and chemotherapy. Notably, 
although the baseline levels of miR-21 predicted resistance 
to trastuzumab-chemotherapy treatment, we found that 
its expression was further upregulated after such therapy 
( p = 0.016) (Figure 1B). These data indicate that an 
additional increase in miR-21 induced by the current 
therapy may sustain a molecular loop responsible for drug 
resistance in HER2-positive breast cancer. To further assess 
the ability of miR-21 to discriminate the patients’ responses 
to trastuzumab-based therapy, we performed a receiver-
operating characteristic (ROC) analysis of the validation 
dataset. The results of this analysis confirmed that miR-21 
expression was able to discriminate patients who achieved 
a pCR from those with RD after neoadjuvant therapy with 
high accuracy (AUC = 0.772) (Figure 1C).
MiR-21 downregulates PTEN and PDCD4 
contributing to trastuzumab-chemotherapy 
resistance in patients with HER2-overexpressing 
breast cancer
To evaluate the role of miR-21 in determining 
the drug response of HER2-positive breast cancers, we 
performed in vitro assays using a HER2-positive breast 
cancer cell line (SKBR3) treated with a miR-21 inhibitor 
alone or in combination with chemotherapeutic drugs 
or trastuzumab. The miR-21 inhibitor alone was able 
to decrease the viability of untreated cells ( p = 0.042), 
but it was less effective than treatment with paclitaxel 
( p = 0.001), doxorubicin ( p = 0.002), and trastuzumab 
( p = 0.002) (Figure 2). Notably, the inhibition of miR-21 
significantly increased the ability of paclitaxel ( p = 0.005), 
doxorubicin ( p = 0.001), and trastuzumab ( p = 0.004) 
to reduce the viability of SKBR3 cells, indicating that 
miR-21 is involved in both trastuzumab and chemotherapy 
resistance (Figure 2).
To investigate the molecular mechanisms underlying 
miR-21-mediated therapy resistance, we searched for 
predicted and validated target genes by combining 
several target prediction databases, including miRBase 
(http://microrna.sanger.ac.uk), TargetScan (http://www 
.targetscan.org), and Tarbase (http://diana.cslab.ece.ntua.
gr/tarbase). Based on these analyses and the biological 
roles played in EMT and immune signaling [13, 27], PTEN 
and PDCD4 were selected for further evaluation. We found 
that inhibition of miR-21 substantially increased PTEN 
and PDCD4 expression in SKBR3 cells (Supplementary 
Figure 1), confirming that both proteins are direct targets 
of miR-21. Furthermore, both PTEN (rs = −0.502; 
p = 0.005) (Figure 3A, 3B) and PDCD4 (rs = −0.426; 
p = 0.019) (Figure 3C, 3D) protein expression significantly 
and inversely correlated with the expression of miR-21 
in HER2-positive breast cancer patients. However, only 
PTEN showed a mild association with response to therapy 
( p = 0.033) (Supplementary Table 2). Overall, these 
findings suggest that the reduced expression of these 
Table 1: MicroRNAs differentially expressed between responders and non-responders in 
HER2-positive and HER2-negative breast cancer patients
HER2-positive HER2-negative
Fold Change p-value Fold Change p-value
let-7b –1.177 0.621 –1.258 0.211
miR-20a –1.116 0.812 –1.095 0.943
miR-21 –4.989 0.030 2.589 0.276
miR-34a –1.427 0.373 1.275 0.562
miR-106b 1.825 0.337 –2.470 0.303
miR-107 –1.160 0.503 –1.020 0.905
miR-145 1.473 0.597 –1.270 0.930
miR-155 –1.968 0.198 1.975 0.190
miR-181b –1.438 0.277 1.054 0.432
miR-200b 1.516 0.621 1.629 0.203
miR-221 –1.021 0.668 1.273 0.370
miR-495 1.197 0.817 –1.101 0.967
Significant p-values are given in bold
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Figure 1: Overexpression of miR-21 in HER2-overexpressing breast cancer is associated with trastuzumab and 
chemotherapy resistance. A. MiR-21 is significantly overexpressed in patients with RD compared with patients who achieved pCR 
( p = 0.012). B. miR-21 expression was significantly higher in HER2-positive patients after trastuzumab and chemotherapy treatment 
( p = 0.016). *p < 0.05; **p ≤ 0.01. C. The ROC analysis demonstrated that miR-21 expression was able to discriminate patients with pCR 
from those with RD with high accuracy (AUC = 0.772).
Figure 2: Effect of miR-21 inhibition on the sensitivity of SKBR3 breast cancer cells to trastuzumab and 
chemotherapeutic agents. Following transfection with a negative control or miR-21 inhibitor, SKBR3 cells were treated with paclitaxel 
(5 nM), doxorubicin (1 μM), or trastuzumab (10 μg/mL), and cell viability was assessed with an MTT assay. MiR-21 inhibition alone and 
drug treatments reduced cell viability compared with untreated cells. Importantly, the inhibition of miR-21 significantly increased the ability 
of both chemotherapeutic drugs and trastuzumab to reduce the viability of SKBR3 cells. All experiments were performed in triplicate. Error 
bars represent the S.D. *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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protein markers alone may not be sufficient to predict 
response to preoperative trastuzumab and chemotherapy.
To further explore the role of these targets in miR-21-
mediated drug resistance, we evaluated the effects of PTEN 
and PDCD4 silencing on the viability of SKBR3 cells treated 
with paclitaxel, doxorubicin, or trastuzumab (Figure 4). We 
found that a reduction of PTEN consistently increased the 
viability of untreated cells ( p = 0.022) and enhanced the 
resistance of SKBR3 cells to treatments with doxorubicin 
( p = 0.012) and trastuzumab ( p = 0.001), but failed to affect 
the viability of paclitaxel-treated cells (Figure 4A, 4B). 
Conversely, the downregulation of PDCD4 slightly increased 
the survival of untreated cells ( p = 0.036), and significantly 
reduced the sensitivity of SKBR3 cells to both paclitaxel 
( p = 0.005) and doxorubicin ( p = 0.001) (Figure 4C, 4D). 
These results suggest that distinct molecular mechanisms, 
specifically those affecting the sensitivity to different drugs, 
may be responsible for the miR-21-mediated resistance to 
trastuzumab and chemotherapy in HER2-positive cancer 
cells.
MiR-21 signaling is involved in an EMT-
reinforcing loop that exerts immunomodulatory 
functions in HER2-positive breast cancer cells 
upon PI3K pathway activation
To further elucidate the functional role of miR-21 
associated with drug resistance, we investigated its 
involvement in the induction of a local immune response, 
which may sustain EMT in HER2-overexpressing cancer 
cells. Our data demonstrated that PTEN silencing, but 
not PDCD4 silencing, increased the release of IL-6 from 
SKBR3 cells ( p = 0.001) (Figure 5A), and that the direct 
stimulation of cells with IL-6 increased the expression 
of miR-21 ( p = 0.016) (Figure 5B). In addition, IL-6 
induced EMT, as indicated by the down-regulation 
of E-cadherin and the up-regulation of vimentin, 
activated the PI3K pathway (via the downregulation 
of PTEN and up-regulation of phosphorylated AKT), 
and triggered an inflammatory loop by increasing the 
levels of phosphorylated STAT3 and NF-κB proteins 
(Figure 5C). Overall, these results suggest that miR-21 
signaling sustains EMT in these cancer cells to cause 
tumor progression and therapy resistance, and may affect 
the tumor immune microenvironment by activating IL-6 
signaling. In support of these findings, we also found that 
HER2-positive tumors expressing high levels of miR-21 
showed a significant high content of CD68-positive 
macrophages (rs = 0.417; p = 0.022), supporting the 
immunomodulatory role of this miRNA (Figure 5D).
DISCUSSION
The addition of trastuzumab to cytotoxic therapies 
has significantly improved the response rates and outcomes 
of HER2-positive breast cancer patients. Despite this 
Figure 3: PTEN and PDCD4 protein levels correlate with miR-21 expression in HER2-positive breast cancer. The 
expression levels of PTEN (A, B) and PDCD4 (C, D) were assessed in the validation cohort by immunohistochemistry and graded as 
follows: low expression, score 0–1; high expression, score 2–3. A. Representative images of PTEN expression in samples with low (a) 
and high (b) miR-21 expression. B. Correlation between miR-21 expression and PTEN protein levels in HER2-positive breast cancers 
tissues (rs = –0.502; p = 0.005). C. Representative images of PDCD4 expression in samples with low (c) and high (d) miR-21 expression. 
D. Correlation between miR-21 expression and PDCD4 protein levels in HER2-positive breast cancers tissues (rs = –0.426; p = 0.019).
Oncotarget37274www.impactjournals.com/oncotarget
success, drug resistance, particularly to trastuzumab, 
remains an important clinical challenge. Several preclinical 
models have identified different mechanisms of resistance 
[1–9]. However, clinical studies have demonstrated the 
limited value of potential molecular predictors of response 
or resistance to anti-HER2-based therapies [3, 10]. In 
this study, we assessed the expression of a subset of 
specific miRNAs that are involved in the modulation 
of the tumor-associated immune response and EMT 
features and evaluated their association with pCR or 
RD in two independent cohorts of HER2-positive breast 
cancer patients treated with neoadjuvant trastuzumab 
and chemotherapy. The expression of a single miRNA, 
miR-21, was specifically higher in patients with HER2-
amplified breast cancer with RD compared with patients 
who achieved pCR, indicating that miR-21 is an important 
molecular mediator of drug resistance. Consequently, 
we demonstrated that the miR-21 expression levels were 
further amplified following trastuzumab and chemotherapy, 
suggesting a possible increase in metastatic potential. 
Consistent with our findings, chemotherapy-induced DNA 
damage has been shown to upregulate the expression of 
miR-21 by activating NF-κB, which enables breast cancer 
cells to override DNA damage-induced apoptosis and 
enhances their invasiveness [28]. Therefore, higher levels 
of miR-21 may contribute to both primary and acquired 
resistance to trastuzumab-chemotherapy treatment in 
patients with HER2-positive breast cancer. Trastuzumab, 
either in the early or metastatic setting, is co-administered 
with cytotoxic chemotherapy. Thus, the identification 
of reliable markers of trastuzumab resistance should be 
carefully evaluated, and the presence of high levels of 
miR-21 may suggest trastuzumab resistance independently 
of the administered chemotherapy. Overall, our data 
indicate that the measurement of the expression of miR-21 
at baseline or in residual cancer after neoadjuvant therapy 
may be used to understand the likelihood of therapeutic 
response and to select patients harboring HER2-positive, 
drug-resistant tumors who may benefit from novel 
pharmacological agents.
Figure 4: Effects of PTEN and PDCD4 silencing on the viability of HER2-positive breast cancer cells. SKBR3 cells 
were treated with paclitaxel (5 nM), doxorubicin (1 μM), or trastuzumab (10 μg/mL). Cell viability was analyzed using the MTT assay. 
A. PTEN silencing significantly reduced the effect of doxorubicin and trastuzumab. B. The efficiency of PTEN silencing was assessed by 
western blotting. C. PDCD4 silencing enhanced the resistance of SKBR3 cells to paclitaxel and doxorubicin. D. The efficiency of PDCD4 
silencing was assessed by western blotting. Results are presented as percent cell viability relative to controls. Experiments were conducted 
in triplicate, and error bars represent the S.D. *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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Herein, we confirmed that miR-21 is involved in 
EMT and targets PTEN and PDCD4 in HER2-positive 
breast cancer patients, which corroborates previous findings 
[13, 29]. Our data support that the miR-21-mediated 
epigenetic silencing of both tumor suppressor genes, 
particularly PTEN, could be an important mechanism of 
resistance to trastuzumab-chemotherapy in patients with 
HER2-positive tumors. As a result, we demonstrated that 
the downregulation of PTEN and PDCD4 differentially 
influenced the sensitivity of HER2-positive breast cancer 
cells to current drugs. Several experimental models 
have proven that the activation of the PI3K pathway, 
especially via the loss of PTEN, is responsible to determine 
resistance to trastuzumab [3–8]. Notably, a lack of PTEN 
expression only marginally correlated with RD after 
neoadjuvant trastuzumab-chemotherapy in this study. 
These findings are supported by recent studies that suggest 
that a loss of PTEN is associated with poor outcome 
but has very limited predictive value to measure the 
response to trastuzumab-based therapy [30, 31]. Potential 
explanations for these conflicting results are linked to a 
lack of standardization for PTEN status determination and 
Figure 5: The miR-21 signaling is involved in an EMT loop that exerts important immunomodulatory functions. A. The 
release of IL-6 was consistently increased by the silencing of PTEN in SKBR3 cells. B. Treatment of SKBR3 cells with recombinant 
IL-6 increased the expression of miR-21. C. IL-6 induced EMT by upregulating specific mesenchymal markers, such as vimentin, and 
downregulating epithelial markers, such as E-cadherin. Furthermore, IL-6 triggered the activation of the PI3K pathway via the suppression 
of PTEN and phosphorylation of AKT, which activated an inflammatory signaling cascade by increasing the levels of phosphorylated 
STAT3 and NF-κB in SKBR3 cells. D. Representative images of CD68 protein expression assessed by immunohistochemistry in the 
validation cohort. Breast cancer samples expressing high levels of miR-21 showed high CD68 staining (rs = 0.417; p = 0.022), supporting 
the immunomodulatory role of miR-21. The data are presented as the mean ± SD of three independent experiments.*p < 0.05; ***p ≤ 0.001.
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consequent challenges of reproducibility across different 
studies, complex mechanisms of drug resistance, and 
confounding effects from different types of concomitant 
chemotherapies [3, 5, 10]. These findings, together with 
the lack of association between PDCD4 and response to 
trastuzumab and chemotherapy treatment, suggest that 
either PTEN or PDCD4 alone, likely may not reliably 
predict the response of HER2-positive breast cancer 
patients to therapy. Conversely, we demonstrated that 
the inhibition of miR-21 synergistically increased the 
ability of chemotherapeutic agents and trastuzumab to 
reduce the viability of HER2-positive breast cancer cells. 
These results indicate that miR-21 leads to resistance to 
trastuzumab and chemotherapy via different mechanisms, 
confirming that miR-21 could serve as a comprehensive 
predictive marker of response to such therapy for HER2- 
positive breast cancer patients.
Despite the important role of miR-21-mediated 
PTEN and PDCD4 deficiency in drug resistance, the 
response to anti-HER2 and chemotherapeutic agents 
may be dependent on additional mechanisms, including 
the boosting of a local inflammatory signaling, which 
is responsible for the release of specific cytokines and 
the expansion of tumor cells with an EMT phenotype 
[13, 18, 28]. Consistently, we found that PTEN silencing 
increased the production of IL-6, which consequently 
increased the expression of miR-21 and induced EMT. 
Our results are in agreement with previous findings 
showing that the release of IL-6 by mesenchymal cancer 
cells and tumor-associated macrophages was able to 
induce EMT and macrophage polarization toward a 
pro-tumoral M2 profile [13, 18, 19, 32, 33]. In addition, 
our in vitro assays demonstrated that the silencing of 
PTEN in HER2-amplified breast cancer cells was indeed 
able to activate the PI3K pathway and an inflammatory 
signaling cascade driven by the STAT3/NF-κB pathway. 
The activation of both PI3K/AKT and STAT3 signaling 
has been recognized to shape the tumor immune 
microenvironment and modulate the anti-tumor immune 
response, which emphasizes the therapeutic potential 
of targeting both oncogenic and immune checkpoint 
pathways (e.g. PD-1 or CTLA4) in drug-resistant HER2-
positive breast tumors [34]. Furthermore, we demonstrated 
that miR-21 overexpression correlated with the infiltration 
of macrophages, suggesting a potential crosstalk between 
the tumor and immune microenvironment that sustains 
an EMT phenotype and drug resistance in HER2-positive 
cancer cells. Our data are reinforced by the association 
between a low content of macrophages and the response 
to neoadjuvant therapy, as well as the increased overall 
survival of HER2-positive breast cancer patients [35]. 
The infiltration of macrophages is responsible for the 
recruitment of tumor-infiltrating lymphocytes, which 
are now emerging as potential prognostic, and possibly 
predictive, factors in HER2-positive breast cancers 
[35–38]. Indeed, clinically relevant reciprocal crosstalk 
between adaptive and innate immune cells, particularly 
macrophages and T lymphocytes, has been demonstrated 
in breast cancer, and warrants further study [35, 39].
Collectively, these results suggest that miR-21 
overexpression may be used as a comprehensive predictive 
biomarker of trastuzumab-chemotherapy resistance and 
that patients harboring HER2-positive tumors expressing 
high levels of miR-21 may benefit from the addition of 
PI3K inhibitors or immunomodulatory drugs to current 
anti-HER2 therapies.
MATERIALS AND METHODS
Patients characteristic and tumor samples
Formalin-fixed, paraffin-embedded (FFPE) core 
biopsies were retrospectively collected from 52 patients 
harboring histologically confirmed HER2-positive breast 
cancer who underwent neoadjuvant treatment consisting 
of trastuzumab and chemotherapy at Vall d’Hebron 
University Hospital and Humanitas Clinical and Research 
Institute from 2005 to 2011. Paired post-chemotherapy 
specimens were also available for 12 of these samples. 
Ethical approval was obtained from the review boards 
at the Spanish and Italian Institutions. Tissues from 21 
HER2-negative breast cancer patients who underwent 
neoadjuvant anthracycline- or taxane-based chemotherapy 
were also collected and used as controls. The patient 
characteristics are presented in Supplementary Table 1. 
HER2-overexpressing breast cancer patients were divided 
into a discovery (n = 22) and a validation (n = 30) cohort. 
Response to therapy was dichotomized as pCR (defined 
by the absence of a residual invasive tumor in the breast 
and axillary lymph nodes) or RD. Among the 52 HER2-
positive patients, 28 patients achieved a pCR, whereas the 
other 24 cases had RD (Supplementary Table 1).
RNA isolation and quantitative real-time 
PCR analysis
Total RNA from two 6-μm FFPE sections was 
extracted using a High Pure miRNA Isolation Kit (Roche, 
Milan, Italy) based on the company’s specifications. The 
extracted RNA was then eluted in RNase-free water and 
stored at - 80°C until use. Based on a literature review, 
we selected the most functionally relevant miRNAs 
associated with immune function and EMT regulation (let-
7b-3p, miR-18b-3p, miR-20a-3p, miR-21–5p, miR-34a-5p, 
miR-106b-3p, miR-107, miR-145–3p, miR-155–5p, 
miR-181b-5p, miR-200b-3p, miR-221–3p, miR-373–3p 
and miR-495–3p) and evaluated their expression in 
22 HER2-positive (discovery cohort) and 21 HER2-
negative core biopsies by quantitative real-time PCR 
(qRT-PCR). Briefly, total RNA was reverse transcribed 
using the miRCURY LNA™ Universal RT microRNA 
PCR kit (Exiqon, Vedbaek, Denmark). The expression 
of each miRNA was assayed on the microRNA 
custom Pick-&-Mix panel (Exiqon) in a LightCycler 
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480 Real-Time PCR System (Roche). Negative controls 
without template and the cDNA synthesis control (UniSp6) 
were included. All data were normalized to the average 
of assays detected in all samples (average Ct-assay Ct). 
The two miRNAs expressed in all samples (miR-16–5p 
and let-7a-5p) were used to normalize miRNA expression. 
Upon the selection based on a statistical analysis, the 
expression of miR-21–5p was further analyzed in the 
validation cohort (n = 30). Briefly, 20 ng of total RNA 
from each sample was reverse transcribed using the 
TaqMan MicroRNA Reverse Transcription kit (Life 
Technologies, Monza, Italy). Each amplification reaction 
was performed in triplicate. The miRNA expression was 
quantified in relation to the expression of small nuclear U6 
RNA. The relative expression of miR-21 was calculated 
using the comparative Ct method.
Immunohistochemistry
The 30 samples of the validation cohort were 
subjected to immunohistochemistry (IHC). FFPE sections 
(3 μm) were deparaffinized and subjected to epitope 
retrieval. Tissue sections were treated with Peroxidase 
Blocking Reagent (Dako, Milan, Italy) and Background 
Sniper (Biocare, Milan, Italy) and then incubated with 
antibodies to PTEN (Cell Signaling, Danvers, USA), 
PDCD4 (Abcam, Cambridge, UK), and CD68 (Dako). 
Negative control slides without primary antibody were also 
included in the analysis. Immunodetection was performed 
with the Envision Plus Horseradish Peroxidase Kit (Dako) 
and diaminobenzidine (DAB; Biocare) was used for 
colorimetric visualization followed by counterstaining with 
hematoxylin. The PTEN and PDCD4 expression levels were 
semi-quantitatively scored based on the staining intensity 
(0 = negative; 1 = weak; 2 = moderate; and 3 = strong) 
and the percentage of positive cells (0 < 1%; 1 = 1–25%; 
2 = 26–50%; 3 = 51–80%; and 4 > 80%). Ten visual fields 
from different areas of each tumor were used to evaluate 
the IHC staining. A composite immunoreactive score (IRS) 
was calculated by multiplying the intensity by the percentage 
scores, and the staining intensity was graded as follows: 
0 = IRS 0–3 (negative), 1 = IRS 4–6 (weakly positive), 
2 = IRS 7–9 (positive), and 3 = IRS 10–12 (strongly 
positive). Patients were stratified by low (0–1) or high (2–3) 
PTEN or PDCD4 expression for statistical analyses. The 
CD68 staining was scored based on the infiltration density 
of CD68 positive cells, which ranged from 0 (absent) to 
3 (dense).
Cell cultures and treatments
SKBR3 cell lines were obtained from the American 
Type Culture Collection (ATCC, Manassas, USA). The 
cells were maintained in RPMI containing 10% fetal 
bovine serum (FBS) and penicillin/streptomycin (Life 
Technologies, Monza, Italy) at 37°C in an atmosphere 
of 5% CO2. Trastuzumab was dissolved in sterile water, 
whereas doxorubicin and paclitaxel were dissolved in 
dimethyl sulfoxide (DMSO). The cells were treated with 
paclitaxel (25 nM), doxorubicin (1 μM), trastuzumab 
(10 μg/mL) or control vehicle. Recombinant IL-6 (R&D 
Systems, Minneapolis, USA) was used at a concentration 
of 10 ng/mL.
Cell lines transfection experiments
Small-interfering RNAs (siRNAs) specific to 
human PTEN and PDCD4 (Dharmacon, Lafayette, 
USA) or control siRNA that does not target any 
sequence in the human genome (scrambled) were used 
in transient transfection experiments. We optimized the 
transfection conditions for SKBR3 cells as previously 
described [40]. Gene silencing was performed in three 
replicates in 96-well plates under predetermined optimal 
transfection conditions. Anti-miR-21 inhibitor and its 
corresponding negative control (anti-NC; Ambion, 
Life Technologies) were then transfected into SKBR3 
cells using Lipofectamine 2000 reagent. The final 
concentrations of miR-21 inhibitor and anti-NC were 
30 nmol/L, and the treatments were started 24 h after 
transfection.
Western blotting
The protein extracts were isolated using RIPA 
buffer containing protease inhibitors (Sigma-Aldrich, 
Milan, Italy) and resolved by SDS-PAGE. The antibody 
against anti-PDCD4 was obtained from Abcam. Anti-
E-cadherin, anti-vimentin, anti-PTEN, anti-phospho-
NF-κB (p65), anti-phospho-STAT3, and anti-phospho-
AKT antibodies were purchased from Cell Signaling. 
The membranes were then incubated with the appropriate 
HRP-conjugated secondary antibodies (Millipore, 
Billerica, USA), and the protein signal was detected 
using a chemiluminescent substrate (Millipore). β-actin 
was used as a loading control (Santa Cruz, Heidelberg, 
Germany).
Cell viability assay
Viable cells were identified using the 3-[4, 
5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
assay (MTT; Sigma-Aldrich). Briefly, cells were plated 
(3 × 103 cells/well) on 96-well plates and incubated 
overnight to allow cell attachment. The cells were then 
treated with paclitaxel, doxorubicin, or trastuzumab for 
48 hours. Subsequently, the MTT reagent (5 mg/ml in PBS) 
was added to each well, followed by incubation for 4 h at 
37°C. After the incubation, the MTT crystals in each well 
were solubilized in DMSO, and the absorbance was read at 
560 nm with an iMark plate reader (BioRad, Milan, Italy). 
All treatments were performed in triplicate, and the cell 
viability was expressed as a percentage of the untreated 
control (mean ± S.D.).
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Enzyme-linked immunosorbent assay (ELISA)
The levels of human IL-6 in the serum-free 
conditioned medium of SKBR3 cultured cells were 
determined by ELISA using the DuoSet ELISA 
Development Kit (R&D Systems) following the 
manufacturer’s instructions. All experiments were carried 
out in triplicate and repeated three times.
Statistical analysis
The differential expression of miRNAs between 
patient subgroups was evaluated with a nonparametric 
Mann-Whitney test, and the Wilcoxon-signed rank test 
was used to compare matched samples. To evaluate the 
predictive accuracy of the selected miRNAs, (ROC) 
curves and areas under the curves (AUC) with a 95% 
confidence interval were calculated. The association 
between miRNAs and selected targets was explored with 
Spearman’s correlation analysis. Fisher’s exact test was 
used to compare protein expression levels between groups. 
All tests were two-sided, and the level of significance was 
set to p < 0.05. Statistical analyses were performed using 
GraphPad Prism version 5.
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